Skip to main content

Table 3 Basic data of these quit patients

From: Poor treatment responses were related to poor outcomes in pediatric B cell acute lymphoblastic leukemia with KMT2A rearrangements

Patient

gender

Age (m)

WBC count (× 109/L)

KMT2Ar subtype

Extramedullary involvement

Blast cell at Day 5 (× 109/L)

D19

D46

       

BM smear

FCM-MRD (%)

PCR-MRD

BM smear

FCM-MRD (%)

PCR-MRD

1

M

53

277.97

KMT2A-AFF1

N

3.776

CR

6.21%

Negative

CR

3.54%

Positive

2

M

4

652.28

KMT2A-MLLT1

TL

69.0477

CR

0.50%

Positive

CR

0.00%

Positive

3

M

145

595

KMT2A-AFF1

N

0.8073

CR

1.73%

Positive

CR

0.84%

Positive

4

F

7

136.08

KMT2A-AFF1

N

0

CR

0.00%

Negative

CR

0.00%

Negative

5

M

173

191.89

KMT2A-AFF1

TL

0

CR

0.04%

Positive

CR

0.00%

Positive

6

F

26

23.71

KMT2-MLLT3

N

1.0504

CR

9.05%

Positive

CR

0.11%

Positive

7

M

12

219.52

KMT2A-AFF1

N

36.7445

CR

0.52%

Positive

CR

0.44%

Positive